Orano Med SAS has appointed Frédéric Desdouits as chief executive officer to drive the development of the French biotech company, notably a diversified pipeline of targeted alpha therapies in oncology. Dr Desdouits has been a member of Orano’s governance board since 2022. He was previously CEO of TreeFrog Therapeutics, a French biotech specialising in stem cell-based therapies, and also led the pharmaceutical activities of Seqens, a manufacturer of specialty ingredients. Dr Desdouits holds a PhD in neurosciences from the University of Paris VI Sorbonne, France. Orano’s pipeline includes one advanced clinical programme for AlphaMedix in partnership with Sanofi, and three Phase 1 clinical studies. The company is also setting up its industrial platform to support commercial scale production of its lead-212 targeted alpha therapies.
Orano Med announced the appointment on 8 April 2026.
Copyright 2026 Evernow Publishing Ltd.